Relmada Therapeutics, Inc. (NASDAQ:RLMD) Expected to Announce Earnings of -$1.21 Per Share

Analysts expect Relmada Therapeutics, Inc. (NASDAQ:RLMDGet Rating) to report earnings of ($1.21) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Relmada Therapeutics’ earnings, with estimates ranging from ($1.26) to ($1.12). Relmada Therapeutics posted earnings per share of ($1.34) in the same quarter last year, which suggests a positive year over year growth rate of 9.7%. The business is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Relmada Therapeutics will report full year earnings of ($5.15) per share for the current year, with EPS estimates ranging from ($5.25) to ($4.97). For the next year, analysts expect that the business will post earnings of ($3.77) per share, with EPS estimates ranging from ($5.67) to ($2.50). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Relmada Therapeutics.

Relmada Therapeutics (NASDAQ:RLMDGet Rating) last announced its earnings results on Wednesday, March 23rd. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.20). During the same period in the prior year, the firm posted ($1.28) EPS.

Several research analysts recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Relmada Therapeutics from $69.00 to $53.00 and set a “buy” rating for the company in a research report on Thursday, March 24th. Zacks Investment Research upgraded shares of Relmada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 26th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Relmada Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $38.11.

In related news, Director Paul Edward Kelly sold 10,000 shares of the stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $30.04, for a total value of $300,400.00. Following the completion of the transaction, the director now directly owns 187,295 shares of the company’s stock, valued at $5,626,341.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 11.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in RLMD. Point72 Asset Management L.P. grew its holdings in Relmada Therapeutics by 330.1% in the fourth quarter. Point72 Asset Management L.P. now owns 946,313 shares of the company’s stock worth $21,320,000 after purchasing an additional 726,313 shares during the period. Morgan Stanley grew its holdings in shares of Relmada Therapeutics by 1,604.7% during the third quarter. Morgan Stanley now owns 449,341 shares of the company’s stock valued at $11,777,000 after buying an additional 422,982 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Relmada Therapeutics by 1,468.7% during the third quarter. Millennium Management LLC now owns 254,580 shares of the company’s stock valued at $6,673,000 after buying an additional 238,351 shares during the last quarter. Altium Capital Management LP purchased a new stake in shares of Relmada Therapeutics during the fourth quarter valued at approximately $4,641,000. Finally, BlackRock Inc. grew its holdings in shares of Relmada Therapeutics by 14.5% during the fourth quarter. BlackRock Inc. now owns 1,385,235 shares of the company’s stock valued at $31,211,000 after buying an additional 174,994 shares during the last quarter. Institutional investors and hedge funds own 76.11% of the company’s stock.

Shares of NASDAQ:RLMD opened at $22.40 on Tuesday. Relmada Therapeutics has a 52-week low of $16.23 and a 52-week high of $39.66. The firm has a fifty day moving average of $24.53 and a 200 day moving average of $21.94. The firm has a market capitalization of $659.30 million, a PE ratio of -3.14 and a beta of 0.51.

Relmada Therapeutics Company Profile (Get Rating)

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.

Recommended Stories

Get a free copy of the Zacks research report on Relmada Therapeutics (RLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Relmada Therapeutics (NASDAQ:RLMD)

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.